Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles
Pavlos R, McKinnon EJ, Ostrov DA, Peters B, Buus S, Koelle D, Chopra A, Schutte R, Rive C, Redwood A, Restrepo S, Bracey A, Kaever T, Myers P, Speers E, Malaker SA, Shabanowitz J, Jing Y, Gaudieri S, Hunt DF, Carrington M, Haas DW, Mallal S, Phillips EJ. Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Scientific Reports 2017, 7: 8653. PMID: 28819312, PMCID: PMC5561238, DOI: 10.1038/s41598-017-08876-0.Peer-Reviewed Original ResearchConceptsHypersensitivity reactionsHLA moleculesTreatment-limiting hypersensitivity reactionClass IDrug hypersensitivity syndromeHuman leukocyte antigen (HLA) systemHLA class IHLA-C allelesClass II allelesLeukocyte antigen systemHLA-B allelesNevirapine hypersensitivityHypersensitivity syndromeHLA associationsIndependent associationHLA-DRB1T cellsImmune responseNovel risk allelesPathogenic mechanismsDrug specific interactionsMultiple class IAntigen systemPrimary predispositionRisk alleles